A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
This study has been completed.
Sponsor:
Astellas Pharma Inc
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00739453
First received: August 19, 2008
Last updated: December 21, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | December 2011 |
| Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |